An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
This is an expanded access, open-label, multicenter program of ruxolitinib for treatment of chronic GVHD, for patients who have received a bone marrow transplant (allogeneic hematopoietic stem cell transplant, or allo-HSCT) and developed GVHD not responsive to steroid treatment and who are not eligible to participate in an actively-enrolling study for treatment of GVHD sponsored by the pharmaceutical company Incyte Corporation within the US.
Chronic Graft-versus-Host disease
Steroid refractory or intolerant cGVHD
Patients who have steroid refractory or intolerant chronic graft-versus-host disease (cGVHD).
12 - 100
Healthy Volunteers Needed
Duration of Participation
Eligible patients may receive ruxolitinib treatment for as long as clinical benefit is observed and/or treatment withdrawal criteria are not met as per discretion of treating physician.
Knight Cancer Intake Center: (503)494-7999
Clinical Trials Information Line: (503)494-1080 or email@example.com